by nms-sync | Apr 5, 2023 | News
Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting
NMS-812: A potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting...
by nms-sync | Apr 5, 2023 | News
Nerviano, 05/04/2023
NMS Group certificato di nuovo come “Luogo di lavoro che promuove salute” nel 2022
NMS group dal 2017 aderisce con gran orgoglio al programma WHP , progetto di Regione Lombardia e ATS Città Metropolitana di Milano che si pone...
by nms-sync | Apr 4, 2023 | News
NERVIANO, 4 April 2023 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Phase I/II clinical study of...
by nms-sync | Mar 1, 2023 | News
NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm...
by nms-sync | Feb 1, 2023 | News
NERVIANO, IT and BOSTON, Mass, 01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today...
by nms-sync | Jan 13, 2023 | News
NERVIANO, IT and BOSTON, Mass, January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the...
Welcome and Check out our new motion picture!
Recent Comments